logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics adds new siRNA asset to pre-clinical pipeline for potential treatment of cardiovascular disease

The firm, a leader in the discovery, development and delivery of novel RNA therapeutics, said the proprietary product candidate, SLN360, silences apolipoprotein, a component of lipoprotein(a) (LP(a)

Therapeutics testing
Silence Therapeutics said that an Investigational New Drug/Clinical Trials Application for SLN360 is anticipated to be filed in the second half of 2020

Silence Therapeutics PLC (LON:SLN) has added a new siRNA (short interfering RNA) asset to its pre-clinical pipeline for the potential treatment of cardiovascular disease.

The firm, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, said the proprietary product candidate, SLN360, silences apolipoprotein, a component of lipoprotein(a) (LP(a).

WATCH: Silence Therapeutics CEO looks ahead to clinical trial next year and prospects for RNAi

David Horn Solomon, of Silence Therapeutics‘ chief executive officer, commented: "We are excited to add SLN360, our new LP(a) targeting siRNA medicine, to our pipeline of wholly-owned assets aimed at addressing areas of significant unmet need.”

He added: “High LP(a) levels in humans increase the probability of significant cardiovascular disease and lowering these levels is associated with reducing cardiovascular risks and disease. Our data suggest that SLN360 significantly reduces serum LP(a) in non-human primates for up to two months and ultimately will use patient convenient sub-cutaneous dosing."

“We are poised to advance SLN360 towards the clinic as a new medicine for patients with significant cardiovascular risk," Solomon concluded.

Silence Therapeutics said that an Investigational New Drug/Clinical Trials Application for SLN360 is anticipated to be filed in the second half of 2020.

In a note to clients, analysts at ‘house’ broker Peel Hunt said: “We see this as a positive step for the company as new management focus much more on the building the pipeline – adding this to the Silence’s asset for beta-thalassemia and myelodysplastic syndrome (SLN124).”

They added: “We continue to review our valuation methodology following resolution of the recent litigation but this asset will add NPV to the portfolio/platform on a risk-adjusted basis.”

In mid-morning trading, Silence Therapeutics’ shares were 0.7% higher at 55.20p.

 -- Adds analyst comment, share price --

Quick facts: Silence Therapeutics PLC

Price: 386 GBX

AIM:SLN
Market: AIM
Market Cap: £302.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Silence Therapeutics 'charging ahead with its key...

David Solomon, chief executive of Silence Therapeutics PLC (LON:SLN), updates on developments across their three key programmes - SLN 500, 124 and 360. Discussing the firm's current valuation, Solomon says ''there's a lot more steam in the engine''. ''I think that's what's exciting - we're...

2 weeks, 2 days ago

2 min read